
This study reveals that pyrithione zinc (PYZ), an FDA-approved drug, enhances tumor immunogenicity in mismatch repair proficient (pMMR) cancers by inhibiting DNA mismatch repair (MMR) proteins MSH2 and MSH6 and activating STING signaling. PYZ increases ROS levels, HIF-1α expression, and DNA damage, which together stimulate STING-mediated immune responses. In vivo, PYZ promotes CD8+ T cell infiltration and inhibits tumor growth, offering a potential strategy to improve immunotherapy efficacy for pMMR cancers.
Like
Save
Share